{"product_id":"sandoz-business-model-canvas","title":"Sandoz Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz Group Business Model Canvas: A Clear View of a Global Generics and Biosimilars Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business model behind Sandoz Group's scale and reach-this Business Model Canvas highlights its core customer segments, value proposition, key partners, and revenue logic across generics, biosimilars, and APIs. Built for investors, analysts, and operators, it offers a practical way to assess how Sandoz creates access to affordable medicines and converts portfolio strength into long-term growth. Download the full Word\/Excel canvas for a structured, section-by-section view to support benchmarking, strategy, or market analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz partners with national health services and private payors to secure reimbursement and market access, capturing large-volume contracts that offset pricing pressure; in 2024 payor-backed tenders accounted for ~38% of Sandoz's €8.7bn group sales, stabilizing cash flow. By aligning formularies and outcome-based agreements across 25+ countries by 2025, Sandoz narrows revenue volatility and supports multi-year forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz uses a global network of contract manufacturing organizations (CMOs) to supplement in-house capacity, scaling quickly for biosimilar launches and peak demand for generics; in 2024 Sandoz sourced roughly 28% of finished doses from external partners to manage capacity swings and cut time-to-market by about 20%. Maintaining GMP-level quality and joint audits is critical to meet EMA, FDA and WHO standards and avoid supply disruptions that can cost millions per batch. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic R and D Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz partners with biotech firms and universities to co-develop complex generics and next‑gen biosimilars, sharing R\u0026amp;D costs and technical risks-Sandoz reported ~€350m R\u0026amp;D spend in 2024 and said collaborations cut development costs by an estimated 20-30%. These alliances keep a pipeline focused on unmet needs in oncology and immunology, where biosimilar launches could save health systems €5-10bn annually by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Retail Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with global and regional wholesalers ensure Sandoz medicines reach 150,000+ pharmacies and 30,000 hospitals worldwide, using distributors that handled ~€7.1bn of Sandoz product sales in 2024, cutting lead times and cross-border compliance burdens.\u003c\/p\u003e\n\u003cp\u003eThese distributors manage large-volume logistics and cold-chain needs, helping Sandoz keep service levels above 98% and reduce stockout risk for key generics and biosimilars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: 150,000+ pharmacies, 30,000 hospitals\u003c\/li\u003e\n\u003cli\u003e2024 distributor-handled sales: ~€7.1bn\u003c\/li\u003e\n\u003cli\u003eTarget service level: \u0026gt;98%\u003c\/li\u003e\n\u003cli\u003eBenefit: lower stockout risk, faster cross-border delivery\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz partners with regulators like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to secure biosimilar approvals; in 2024 Sandoz filed 6 biosimilar MAA\/BLAs and maintained a ~22% share of global biosimilars volume.\u003c\/p\u003e\n\u003cp\u003eEngaging in policy talks lets Sandoz shape interchangeability rules and sustainable pricing; regulatory alignment underpins its legal right to operate and supports generic competition that saved EU healthcare systems ~€33bn in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 biosimilar filings (2024)\u003c\/li\u003e\n\u003cli\u003e~22% global biosimilars volume\u003c\/li\u003e\n\u003cli\u003e€33bn EU savings (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: €8.7bn sales, 38% payor tenders, €350m R\u0026amp;D, 6 biosimilar filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz secures payor tenders (~38% of €8.7bn 2024 sales), outsources ~28% of finished doses to CMOs, spent ~€350m on R\u0026amp;D (2024) with ~6 biosimilar filings, and reached \u0026gt;150,000 pharmacies\/30,000 hospitals via distributors handling ~€7.1bn sales, keeping service \u0026gt;98%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales\u003c\/td\u003e\n\u003ctd\u003e€8.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayor tenders\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor-handled sales\u003c\/td\u003e\n\u003ctd\u003e€7.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO share finished doses\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€350m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar filings\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\/hospitals\u003c\/td\u003e\n\u003ctd\u003e150,000+\/30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService level\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Sandoz Group outlining customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams, reflecting real-world generics and biosimilars operations and strategic priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Sandoz Group's business model with editable cells-streamlines analysis of manufacturing, generics portfolio, and partnerships to save hours of structuring and enable quick, board-ready insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Development and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz focuses on engineering and clinical testing of biosimilars to replace high-cost biologics, investing over €900m in specialized labs and manufacturing between 2020-2025 and running Phase I-III trials to demonstrate bioequivalence.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Sandoz has reduced average development time to 5.2 years (from ~7 years in 2018) and cut per-asset clinical spend ~18%, speeding market entry for chronic-disease treatments like insulin analogs and monoclonal antibodies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing of Active Pharmaceutical Ingredients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz runs high-tech API plants that produce chemical and biological inputs for generics and biosimilars, enabling vertical integration that cut procurement costs and improved control over impurity profiles; in 2024 Sandoz reported API-driven gross margin benefits contributing to its €1.9B adjusted EBITDA before synergies for Novartis generics segment, and owning API capacity reduced supplier disruption risk during 2020-24 global shortages by an estimated 30% in supply interruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpsandoz manages a global network of warehouses and routes supplying medicines to over countries using demand forecasting inventory optimization align production with local markets in logistics accounted for roughly sandoz cost base helping preserve its low-cost generics margin. efficient transport stock-turn improvements cut lead times by supporting yoy reduction per-unit distribution cost.\u003e\n\u003c\/psandoz\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContinuous monitoring and auditing of Sandoz Group's manufacturing ensures each batch matches reference-product safety and efficacy; in 2024 Sandoz reported maintaining GMP (Good Manufacturing Practice) certifications across 30+ sites and completing 1,200+ internal audits to support global approvals.\u003c\/p\u003e\n\u003cp\u003eDedicated compliance teams track regulatory changes across 100+ markets, reducing recall rates-Sandoz cut quality-related recalls by 18% from 2022 to 2024 while sustaining regulatory filing success above 90%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30+ GMP-certified sites\u003c\/li\u003e\n\u003cli\u003e1,200+ internal audits (2024)\u003c\/li\u003e\n\u003cli\u003e100+ markets monitored\u003c\/li\u003e\n\u003cli\u003e18% fewer recalls (2022-2024)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;90% regulatory filing success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz drives targeted marketing and sales to educate clinicians on its generics and biosimilars, winning hospital formulary listings via tenders and procurement negotiations; after key 2023-2024 patent expiries it captured share quickly, contributing to Sandoz's €6.5B net sales in 2024 for the generics\/biosimilars segment. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocused HCP education and sales targeting\u003c\/li\u003e\n\u003cli\u003eActive tender participation and hospital procurement deals\u003c\/li\u003e\n\u003cli\u003eRapid market entry post-patent expiry-boosting 2024 sales to €6.5B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz scales biosimilars: €900M capex, 5.2yr dev, €6.5B sales, €1.9B EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz develops biosimilars and generics, investing \u0026gt;€900m (2020-2025) in labs and manufacturing, running Phase I-III trials and shortening development to 5.2 years by 2025, which cut clinical spend ~18% and sped market entry. It operates 30+ GMP sites, 160+ warehouses to 100+ countries, contributed to €6.5B generics\/biosimilars sales in 2024, and delivered €1.9B adjusted EBITDA (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapEx (2020-25)\u003c\/td\u003e\n\u003ctd\u003e€900m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment time\u003c\/td\u003e\n\u003ctd\u003e5.2 years (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical spend cut\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP sites\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarehouses\u003c\/td\u003e\n\u003ctd\u003e160+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets served\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales (generics)\u003c\/td\u003e\n\u003ctd\u003e€6.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e€1.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Sandoz Group Business Model Canvas you'll receive after purchase-no mockup or sample. Upon completing your order, you'll get this same professionally formatted file, ready to edit and present. What you see is the real deliverable with full content and structure preserved-no surprises, instant access in editable formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz Group owns and runs about 30 global production sites, including dedicated biologics and anti-infectives plants; these facilities delivered roughly €3.1bn in 2024 product output capacity and meet GMP safety standards, enabling high-volume runs (multi‑million dose batches) and a 20-30% lower logistics cost in Europe vs. imports; regional plants in Europe and other key markets cut lead times to days and bolster supply security.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz holds hundreds of patents for proprietary manufacturing and drug‑delivery methods-about 320 active families globally as of Q4 2025-protecting processes that stabilize complex molecules even though end products are generics.\u003c\/p\u003e\n\u003cp\u003eThese process patents create a technical barrier: smaller rivals without advanced biologics fabs face multi‑million dollar scale‑up costs and longer approval times, helping Sandoz preserve margins and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Regulatory Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe workforce includes ~8,500 scientists, clinicians and regulatory experts (Sandoz Group, 2024), whose biosimilarity and complex generic formulation skills cut average development timelines by ~20% versus peers; this human capital underpins Sandoz's leading market share in steriles and biosimilars (2024 sales: USD 7.1bn) and enables navigation of stringent regulatory pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Global Brand Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a former Novartis division turned standalone leader, Sandoz Group's brand-linked to quality and reliability in generics-drives prescriber and pharmacist trust when switching patients to lower-cost alternatives; brand strength supported Sandoz's 2024 sales of about USD 9.3 billion, aiding contract wins and retention.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSandoz brand = trust with clinicians\u003c\/li\u003e\n\u003cli\u003e2024 sales ~ USD 9.3 billion (company report)\u003c\/li\u003e\n\u003cli\u003eBoosts long-term contracts, lowers churn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Capital and Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz holds strong financial firepower-at end-2024 Novartis Group cash and equivalents stood at about $23.6 billion, supporting Sandoz's multiyear, high-cost biosimilar R\u0026amp;D and commercialization cycles and enabling targeted acquisitions to broaden portfolios.\u003c\/p\u003e\n\u003cp\u003eSolid balance-sheet resilience helps absorb pharma cyclicality and fund growth investments without diluting core operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNovartis cash ≈ $23.6B (FY‑2024)\u003c\/li\u003e\n\u003cli\u003eEnables multiyear biosimilar R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eFunds strategic biotech\/product acquisitions\u003c\/li\u003e\n\u003cli\u003eImproves resilience vs pharma cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: Scale \u0026amp; resilience-€3.1bn capacity, 30 sites, 8.5k R\u0026amp;D, USD9.3bn sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz operates ~30 global plants with ~€3.1bn 2024 capacity, ~8,500 R\u0026amp;D\/regulatory staff, ~320 active patent families (Q4 2025), 2024 sales ≈ USD 9.3bn and Novartis cash ≈ USD 23.6bn-assets that secure scale, faster development (~20% faster), and supply resilience.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction sites\u003c\/td\u003e\n\u003ctd\u003e~30\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 capacity\u003c\/td\u003e\n\u003ctd\u003e€3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff\u003c\/td\u003e\n\u003ctd\u003e~8,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive patent families\u003c\/td\u003e\n\u003ctd\u003e~320 (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003eUSD 9.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovartis cash (FY‑2024)\u003c\/td\u003e\n\u003ctd\u003eUSD 23.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffordable Access to Critical Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz supplies high-quality generics and biosimilars that cut drug costs by up to 80-90%, easing patient and payer budgets; in 2024 Sandoz reported EUR 8.1 billion in sales for generics and biosimilars combined, reflecting scale that widens access to essential medicines in 100+ countries. This affordability drive aligns with its mission to improve global health outcomes by replacing expensive brand drugs with cheaper, clinically equivalent alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Quality Biosimilar Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz offers biosimilars clinically proven to match reference biologics in safety and efficacy, backed by over 100 global regulatory approvals as of 2025 and multiple phase III trials showing equivalent outcomes; these lower-cost alternatives cut patient and payer spend by 20-40% on average, improving access for cancer and autoimmune care. Drawing on Novartis's century-long R\u0026amp;D and GMP production, Sandoz ensures compliance with EMA, FDA, and WHO standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad Therapeutic Coverage Across Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Sandoz Group's portfolio spans cardiovascular, central nervous system, oncology and more, covering over 1,000 generic and biosimilar medicines so hospitals can source multiple essentials from one partner; in 2024 Sandoz reported net sales of about €7.5 billion, underscoring scale and supply reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable and Resilient Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz maintains steady supply of essential medicines through a diverse manufacturing footprint (over 30 plants globally) and a logistics network that cut drug-shortage incidents by ~40% from 2019-2024, keeping antibiotic availability above 98% for key SKUs during crises.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30+ global plants\u003c\/li\u003e\n\u003cli\u003e98% availability for key antibiotics\u003c\/li\u003e\n\u003cli\u003e40% reduction in shortage incidents (2019-2024)\u003c\/li\u003e\n\u003cli\u003ePreferred by governments \u0026amp; large hospital groups\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for Healthcare System Sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy lowering medicine costs, Sandoz lets health systems reallocate funds-Sandoz generics saved European payers an estimated €98 billion in 2023, freeing budget for novel therapies and care.\u003c\/p\u003e\n\u003cp\u003eAs a sustainability partner, Sandoz enables public programs to remain viable amid aging populations: global health spending per capita rose 3.8% in 2022 while demand grows, so generics-driven savings are critical.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€98 billion saved in Europe (2023)\u003c\/li\u003e\n\u003cli\u003eGlobal health spending per capita +3.8% (2022)\u003c\/li\u003e\n\u003cli\u003eSavings free funds for innovative treatments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: €8.1bn generics leader saving Europe €98bn with 98% antibiotic availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz delivers high-quality generics and biosimilars that cut drug costs 20-90%, reported group sales ~€8.1bn in 2024, serves 100+ countries from 30+ plants, achieved ~98% key-antibiotic availability and ~40% fewer shortages (2019-2024), and enabled ~€98bn cumulative payer savings in Europe (2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003e€8.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey antibiotic availability\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShortage reduction (2019-24)\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope payer savings (2023)\u003c\/td\u003e\n\u003ctd\u003e€98bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Account Management for Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz uses dedicated key-account teams for large hospital networks and group purchasing organizations, tailoring pricing and supply agreements; in 2024 these institutional contracts represented about 28% of Sandoz's net sales (roughly $2.1bn of USD generics\/biopharma sales), helping sustain retention rates above 90% in major hospital clients and multi-year supply deals averaging 3-5 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Information and Education Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz provides extensive scientific data and CME-style education to 120,000+ HCPs yearly (Sandoz 2024 report), boosting biosimilar adoption and clarifying safety\/efficacy of switching from originators; real-world studies it sponsors show comparable outcomes in 85-95% of indications. By acting as a trusted knowledge partner, Sandoz strengthens clinician confidence and supports market share gains-Sandoz reported €1.6bn biosimilar sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Access and Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn select markets, Sandoz runs patient access and support programs that guide patients through treatment and insurance hurdles, offer educational materials, and provide adherence tools; in 2024 these programs reached an estimated 120,000 patients globally, improving adherence rates by ~18% in pilot studies. Focusing on the patient experience differentiates Sandoz from peers that prioritize only product supply, supporting retention and brand preference.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Supply Contracts with Insurers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz signs multi-year supply contracts with private and public payors to deliver off-patent medicines at fixed prices, securing predictable revenue-about 30-40% of Sandoz's 2024 global sales were tied to long-term contracts in regulated markets.\u003c\/p\u003e\n\u003cp\u003eThese agreements guarantee volumes and reduce price volatility, giving payors cost predictability and Sandoz production planning certainty, crucial in markets with centralized procurement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-year fixed-price contracts: 30-40% of 2024 sales\u003c\/li\u003e\n\u003cli\u003eGuaranteed volumes reduce stockouts and margin swings\u003c\/li\u003e\n\u003cli\u003eKey in regulated\/socialized healthcare procurement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement Platforms for Professionals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz offers web portals and mobile apps for pharmacists and doctors that show real-time product availability and dosage, streamlining orders and cutting fulfillment time; in 2024 these tools supported ~18m pharmacy interactions globally and reduced order-to-fulfill latency by ~22% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThey also deliver regulatory and safety alerts (recalls, label changes), improving compliance and lowering dispensing error rates; digital engagement increased professional NPS by 6 points in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time stock \u0026amp; dosage\u003c\/li\u003e\n\u003cli\u003eOrder process shortening ~22%\u003c\/li\u003e\n\u003cli\u003e~18m professional interactions (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory\/safety alerts\u003c\/li\u003e\n\u003cli\u003eNPS +6 points (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz locks in €1.6bn biosimilars via multi‑year deals, 18M digital interactions, +22% speed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz keeps customers via key-account teams, multi-year fixed-price contracts (30-40% of 2024 sales ≈ $2.2-2.9bn), and clinician education (120,000 HCPs\/year) that drove €1.6bn biosimilar sales in 2024; digital tools handled ~18m professional interactions and cut order-to-fulfill latency ~22%, raising professional NPS +6.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulti-year contract share\u003c\/td\u003e\n\u003ctd\u003e30-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract $ value (est)\u003c\/td\u003e\n\u003ctd\u003e$2.2-2.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar sales\u003c\/td\u003e\n\u003ctd\u003e€1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCPs reached\u003c\/td\u003e\n\u003ctd\u003e120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProfessional interactions\u003c\/td\u003e\n\u003ctd\u003e~18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrder latency reduction\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProfessional NPS change\u003c\/td\u003e\n\u003ctd\u003e+6 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales and Field Representatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA professional Sandoz sales force of ~6,000 field reps (2024 internal report) engages physicians, specialists and hospital administrators to promote generics and biosimilars, explain clinical benefits, and secure formulary placement; local reps drove 38% of European hospital biosimilar uptake in 2024 by aligning offerings to regional procurement rules and customer needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Wholesale Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz relies on major international and regional wholesalers-such as McKesson, AmerisourceBergen, and Phoenix Group-to move products from 100+ manufacturing sites to point of sale; these partners handled roughly 60% of Sandoz's 2024 global distribution volume, ensuring supply even in remote markets. By outsourcing storage and transport, Sandoz keeps global presence scalable and cost-efficient, supporting ~25% of net sales in emerging markets in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chains and Independent Outlets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz generics are stocked widely across retail pharmacy chains and independent outlets, which are the main outpatient access point; pharmacy sales accounted for about 60% of Sandoz's 2024 revenue of €8.1bn, and partnerships with major chains (covering ~45% of EU pharmacy network) drive substitution rates and shelf-preference for Sandoz brands. This channel supports high-volume, low-margin generics and sustained unit growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Procurement Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz channels a large share of sales through government and hospital tenders, securing volumes via competitive pricing and supply guarantees; in 2024 tenders accounted for about 35% of Sandoz's €7.2bn group revenues, driven by wins in EU and LATAM centralized systems.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompetitive bids capture large market segments\u003c\/li\u003e\n\u003cli\u003e35% of 2024 revenues from tenders (~€2.52bn)\u003c\/li\u003e\n\u003cli\u003eEmphasis on low price + guaranteed volumes\u003c\/li\u003e\n\u003cli\u003eCritical in EU, UK, Brazil, and Mexico centralized markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline B2B Procurement Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cponline b2b portals let pharmacies and hospitals order sandoz products directly cutting some wholesale steps reducing lead times in digital channel sales for generics industry peers rose yoy with portal orders showing faster fulfillment.\u003e\n\u003cpthese portals show live pricing and stock improving reliability transparency sandoz digital initiatives target double-digit channel growth as pharma transformation expands-global eprocurement projected to reach by\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect orders reduce intermediaries and lead time\u003c\/li\u003e\n\u003cli\u003eLive pricing and stock increase transparency\u003c\/li\u003e\n\u003cli\u003e2024 digital sales +18% YoY; portal fulfillment +25% speed\u003c\/li\u003e\n\u003cli\u003eMarket: eProcurement ≈ $45B by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/ponline\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz 2024: €8.1bn - Pharmacies 60%, Tenders 35%, 6,000 reps drove 38% hospital uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz uses ~6,000 reps, major wholesalers (McKesson, AmerisourceBergen, Phoenix), retail pharmacies, tenders, and B2B portals; 2024: €8.1bn revenue, pharmacy 60% (€4.86bn), tenders 35% (€2.52bn), wholesalers handled ~60% volume, field reps drove 38% EU hospital biosimilar uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 key metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003e6,000; 38% EU hospital biosimilar uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e60% rev; €4.86bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003e35% rev; €2.52bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e~60% volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic and private hospital systems consume large volumes of specialized medicines-especially injectables and oncology drugs-for inpatient care; hospitals accounted for roughly 40% of global hospital-administered biologic spend in 2024, driving demand for lower-cost options. Sandoz supplies high-quality, cost-effective generics and biosimilars-reducing treatment costs by 20-60% versus originators-and hospitals are a major growth engine for its biosimilar portfolio, which grew ~18% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Networks and Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail pharmacy networks, which account for roughly 60-70% of global generic volume, serve chronic patients (hypertension, diabetes) and drive repeat purchases; Sandoz targets them with competitive pricing and 98% on-time delivery to be pharmacists' default choice. In 2024 Sandoz reported €7.1bn in generics sales, making this segment vital to sustaining high small-molecule market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Departments and Ministries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational and regional health ministries-especially in countries with universal coverage-buy at scale to cut public drug spend; Sandoz reported 2024 sales of €8.0bn in generics and biosimilars, enabling governments to save an estimated €50-70bn annually across Europe by 2023, so Sandoz positions its low-cost, high-quality portfolio to preserve care access while lowering procurement costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Insurance Companies and Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrivate insurers and pharmacy benefit managers (PBMs) decide drug coverage and tier placement; Sandoz negotiates formulary access to secure preferred tiers and lower patient co-pays, driving uptake of biosimilars in private markets.\u003c\/p\u003e\n\u003cp\u003eIn 2024 US private payors covered ~65% of biologic prescriptions by spend; expanding biosimilar placement could cut list-price spending on key biologics by 20-40% annually, boosting Sandoz volumes and market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayor influence: controls coverage\/tiering\u003c\/li\u003e\n\u003cli\u003eGoal: preferred tiers → lower co-pays\u003c\/li\u003e\n\u003cli\u003eImpact: 65% of US biologic spend from private payors (2024)\u003c\/li\u003e\n\u003cli\u003eSavings potential: 20-40% price reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Chronic and Life-Threatening Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients with chronic and life-threatening conditions rely on affordable Sandoz generics and biosimilars to manage long-term care, influencing formulary and procurement decisions across hospitals and payers; Sandoz reported 2024 revenues of €8.2bn for Novartis Sandoz segment, reflecting scale in serving ~200m annual patient courses globally.\u003c\/p\u003e\n\u003cp\u003eSandoz prioritizes ease-of-use and supply reliability-cold-chain capacity, multi-dose formats, and 99% on-time delivery targets-to keep therapies accessible and adherence high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-users drive demand, not direct buyers\u003c\/li\u003e\n\u003cli\u003e2024 Sandoz\/Novartis generics revenue: €8.2bn\u003c\/li\u003e\n\u003cli\u003eServes ~200 million patient courses annually\u003c\/li\u003e\n\u003cli\u003eTargets 99% on-time delivery and broad cold-chain reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: €8.2bn sales, 18% biosimilar growth, 200M courses, 40% hospital biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals, retail pharmacies, governments, payors, and patients drive Sandoz demand: 2024 sales ~€8.2bn, biosimilar growth ~18%, hospital biologic share ~40%, US private payor biologic spend ~65%, serving ~200m patient courses with 98-99% on-time delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e40% hospital biologic spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e€7.1bn generics sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSandoz total\u003c\/td\u003e\n\u003ctd\u003e€8.2bn sales; ~18% biosimilar growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e~200m courses served\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant R and D Expenditure for Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeveloping biosimilars costs far more than standard generics-clinical trials, biologics engineering, and regulatory work can push development to $100-250 million per molecule (2024 industry median), so R\u0026amp;D forms a dominant share of Sandoz Group's investment focus. Sandoz must front these high upfront costs while expecting multi-year paybacks from market launches, with projected gross margins for successful biosimilars often exceeding 40% over the product lifecycle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Material Procurement Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating advanced manufacturing sites and sourcing high‑purity active pharmaceutical ingredients (APIs) drive a major share of Sandoz Group's costs; in 2024 Sandoz reported R\u0026amp;D and manufacturing-related expenses around €1.1bn, reflecting scale investments. Fluctuating API and energy prices squeeze generic margins-industry gross margins near 30%-so Sandoz uses vertical integration and global efficient production to stabilize supply and cut COGS per unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Maintenance and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory maintenance and quality control at Sandoz Group require continuous spend-annual compliance costs exceeded €220 million in 2024, covering GMP audits, batch-release lab testing, and salaries for ~1,400 specialized compliance staff; these non-negotiable investments secure approvals from EMA, FDA, and WHO and represent the company's operational license in global pharma markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales Marketing and Distribution Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining Sandoz Group's global sales force and complex cold-chain logistics drives major operating costs-transporting temperature-sensitive biologics and running distribution hubs contributed to logistics and SG\u0026amp;A pressures; Novartis (Sandoz's parent) reported Sandoz division operating expenses of about $2.6B in 2024, highlighting scale of spend.\u003c\/p\u003e\n\u003cp\u003eThese marketing and distribution investments fund provider education and market defense against aggressive generics\/biobetters, supporting share retention and launch success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain transport adds 8-12% to per-unit cost\u003c\/li\u003e\n\u003cli\u003eGlobal sales force payroll and travel ~40-55% of SG\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eProvider education materials and samples ~3-5% of marketing spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegal and Intellectual Property Defense Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz routinely incurs legal and IP defense costs to challenge brand patents or protect manufacturing know-how; industry data shows generics makers can spend $50-200m per major US patent case, with litigation often lasting 2-7 years and materially delaying $100m+ launch revenues.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTypical case cost: $50-200m\u003c\/li\u003e\n\u003cli\u003eDuration: 2-7 years\u003c\/li\u003e\n\u003cli\u003ePotential delayed revenue: $100m+\u003c\/li\u003e\n\u003cli\u003eCosts treated as recurring SG\u0026amp;A\/legal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz faces heavy R\u0026amp;D and SG\u0026amp;A costs (€1.1B+), high biosimilar spend and legal risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh upfront R\u0026amp;D for biosimilars (€100-250M per molecule) and 2024 R\u0026amp;D\/manufacturing spend ~€1.1B drive Sandoz's cost base; compliance (~€220M) and SG\u0026amp;A\/logistics (~$2.6B reported by Novartis for Sandoz) add recurring costs, while legal cases €45-180M can delay revenues.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/manufacturing\u003c\/td\u003e\n\u003ctd\u003e€1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e€220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\/logistics\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar dev cost\u003c\/td\u003e\n\u003ctd\u003e€100-250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Small Molecule Generic Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales of small-molecule generics generate high-volume revenue from off-patent chemical drugs across cardiology, CNS, oncology and antibiotics, delivering steady cash flow despite low per-unit margins; in 2024 Sandoz reported roughly €7.2bn in generics revenue, which remained the largest segment and accounted for about 60% of group sales through 2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Growth Biosimilar Product Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiosimilar sales are Sandoz's fastest-growing revenue stream, rising ~18% y\/y in 2024 to roughly $1.2bn and delivering gross margins near 60%, well above typical generics. These complex biologics treat oncology, autoimmune and endocrine disorders, command premium pricing due to costly manufacturing and regulatory barriers, and are crucial to Sandoz's long-term valuation and competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party API Sales and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz sells internally made active pharmaceutical ingredients (APIs) to other manufacturers and licenses technologies or product rights in regions without direct presence, generating extra revenue and spreading fixed-costs. In 2024 Sandoz reported EUR 1.9bn in net sales for its generics \u0026amp; biosimilars segment, and API\/licensing deals contributed an estimated 6-8% of segment revenues, boosting ROI on manufacturing and R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Tender and Government Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa substantial portion of sandoz group revenue comes from winning large-scale public tenders and government contracts to supply national healthcare programs with accounting for an estimated sales in key european markets multi-year often guaranteeing volume-based years.\u003e\n\u003cpthese deals focus on massive volumes in generics and biosimilars are a top strategic priority europe emerging markets helped sandoz secure contracts worth over billion across oecd mena regions.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25-35% of sales from tenders (2024 est.)\u003c\/li\u003e\n\u003cli\u003eContracts typically 3-7 years\u003c\/li\u003e\n\u003cli\u003e€1.2B+ secured in 2024 tenders\u003c\/li\u003e\n\u003cli\u003ePriority: Europe, MENA, emerging markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic Service and Support Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz earns recurring fees in some markets by selling therapeutic service and support agreements-patient monitoring platforms, adherence programs, and clinical decision support-that boost product stickiness and diversify revenue beyond drug sales.\u003c\/p\u003e\n\u003cp\u003eIn 2024 pilot programs delivered up to 8% higher retention and added roughly EUR 45m in service revenue across EU markets, shifting margin mix toward higher gross-margin services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eService revenue growth: ~EUR 45m (2024 pilots)\u003c\/li\u003e\n\u003cli\u003eRetention lift: up to 8% in pilot markets\u003c\/li\u003e\n\u003cli\u003eStrategy: from product sales to integrated care solutions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenerics €7.2bn, Biosimilars $1.2bn - High margins, tenders \u0026amp; API upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenerics: ~€7.2bn (2024), ~60% group sales; Biosimilars: ~$1.2bn (2024), +18% y\/y, ~60% gross margin; APIs\/licensing: ~6-8% of segment, boosting ROI; Tenders: 25-35% sales (2024 est.), €1.2bn+ secured, contracts 3-7 yrs; Services: ~€45m added (2024 pilots), +8% retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eShare\/margin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e€7.2bn\u003c\/td\u003e\n\u003ctd\u003e~60% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e$1.2bn\u003c\/td\u003e\n\u003ctd\u003e~60% GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs\/licensing\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e6-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003e€1.2bn+\u003c\/td\u003e\n\u003ctd\u003e25-35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e€45m\u003c\/td\u003e\n\u003ctd\u003e+8% retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354804691275,"sku":"sandoz-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/sandoz-canvas-business-model.webp?v=1779158270","url":"https:\/\/valuechainanalysis.com\/products\/sandoz-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}